Classen W
Psychiatrische Universitätsklinik, Würzburg.
Psychiatr Prax. 1989 Aug;16 Suppl 1:41-3.
Two groups of depressed patients were treated either with a selective MAO-A-inhibitor, moclobemide (n = 13), or a tetracyclic antidepressant, maprotiline (n = 18), in a 28 days lasting investigation. Before and after treatment psychopathologic symptoms were rated using Hamilton Depression Scale, motor performance were proven by the Motorische Leistungs-Serie (MLS), and acoustic and visual sensorimotor performance were investigated using Bettendorff Reaktiometer T96. Deterioration of psychomotor performance were seen in patients without amelioration of their psychopathologic symptoms, especially when treated with moclobemide. These findings were regarded as a hint that possibly the therapeutic agent interacts with the wrong transmitter system and perhaps this is the reason for the deterioration of psychomotor functions.
在一项为期28天的研究中,两组抑郁症患者分别接受选择性单胺氧化酶A抑制剂吗氯贝胺(n = 13)或四环类抗抑郁药马普替林(n = 18)治疗。治疗前后使用汉密尔顿抑郁量表对精神病理症状进行评分,通过运动能力系列测试(MLS)评估运动表现,并使用贝滕多夫T96反应计研究听觉和视觉感觉运动表现。在精神病理症状未改善的患者中观察到精神运动表现恶化,尤其是接受吗氯贝胺治疗的患者。这些发现被认为是一个提示,即治疗药物可能与错误的递质系统相互作用,这可能是精神运动功能恶化的原因。